Early human B cell signatures of the primary antibody response to mRNA vaccination
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective at inducing protective immunity. However, weak antibody responses are seen in some individuals, and cellular correlates of immunity remain poorly defined, especially for B cells. Here we used unbiased approaches to longitudinally dissect primary antibody, plasmablast, and memory B cell (MBC) responses to the two-dose mRNA-1273 vaccine in SARS-CoV-2-naive adults. Coordinated immunoglobulin A (IgA) and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses but earlier and more intensely after dose 2. While antibody and B cell cellular responses were generally robust, they also varied within the cohort and decreased over time after a dose-2 peak. Both antigen-nonspecific postvaccination plasmablast frequency after dose 1 and their spike-specific counterparts early after dose 2 correlated with subsequent antibody levels. This correlation between early plasmablasts and antibodies remained for titers measured at 6 months after vaccination. Several distinct antigen-specific MBC populations emerged postvaccination with varying kinetics, including two MBC populations that correlated with 2- and 6-month antibody titers. Both were IgG-expressing MBCs: one less mature, appearing as a correlate after the first dose, while the other MBC correlate showed a more mature and resting phenotype, emerging as a correlate later after dose 2. This latter MBC was also a major contributor to the sustained spike-specific MBC response observed at month 6. Thus, these plasmablasts and MBCs that emerged after both the first and second doses with distinct kinetics are potential determinants of the magnitude and durability of antibodies in response to mRNA-based vaccination.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Early human B cell signatures of the primary antibody response to mRNA vaccination
- Date Crossref
- 27/06/2022
- Éditeur
- National Academy of Sciences
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Institutes of Health Critical Care Medicine Department pays non établi dans la noticeOrganisme public
-
National Institute of Allergy and Infectious Diseases NIH Center for Human Immunology pays non établi dans la noticeStructure de recherche
-
Institute for Bioscience and Biotechnology Research pays non établi dans la noticeStructure de recherche
-
Vaccine Research Center pays non établi dans la noticeStructure de recherche
-
National Institutes of Health Clinical Center pays non établi dans la noticeÉtablissement de santé
-
University of Maryland Department of Microbiology and Immunology and Center for Biomolecular Therapeutics pays non établi dans la noticeUniversité ou école supérieure
-
Laboratory of Immunoregulation pays non établi dans la noticeStructure de recherche
-
Laboratory of Immune System Biology Multiscale Systems Biology Section pays non établi dans la noticeStructure de recherche
Critical Care Medicine Department — National Institutes of Health, NIH Center for Human Immunology — National Institute of Allergy and Infectious Diseases et Institute for Bioscience and Biotechnology Research, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.